Bruton’s Tyrosine Kinase: Structure and Functions, Expression and Mutations

Ying Liu1, Guang-biao Zhou2, Bo Zhang1 and Yong-qiang Liu2

1The Shenzhen Key Lab of Gene and Antibody Therapy, Center for Biotech & BioMedicine and Division of Life Sciences, Graduate School at Shenzhen, Tsinghua University, Guangdong, China
2Division of Molecular Carcinogenesis and Targeted Therapy for Cancer, State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, China
3National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, China

Abstract
Bruton’s tyrosine kinase (BTK), a member of the Tec family of protein tyrosine kinases (PTKs), plays a vital and diverse function in many cellular processes. BTK is expressed throughout B cell development, widely participating in multiple signal pathways including PI3K, PLCγ, and PKC. Those pathways play critical functions in cell proliferation, development, differentiation, survival, and apoptosis. The expression of BTK is selectively down-regulated in T lymphocytes and plasma cells and the relative level of BTK expression may be modulated in different developmental populations of B cells. Mutations in the gene for BTK are responsible for X-linked agammaglobulinemia (XLA) in human and X-linked immunodeficiency (Xid) in mice. Both of these diseases are characterized by blocks in B-cell development at multiple stages and impaired function of residual mature B cells. To date, more than 1252 mutations have been identified in human BTK gene associated with XLA. Targeting BTK has achieved remarkable efficacy in B cell malignancies, multiple myeloma and related bone disease. The present review discusses the recent data regarding the role of BTK in B cell development and its structure, regulation, functions, expression and mutations.

Keywords: Bruton’s tyrosine kinase; B cells; Function; Expression; Mutation

Introduction
Non-receptor protein tyrosine kinases are targets in the treatment of a number of diseases. Increasing evidence suggests that these kinases serve multiple roles in diversifying and amplifying the signals emanating from receptors located on the cell surface [1,2]. The Tec family formed by BTK, BMX, ITK, TEC, and RLK, are the second largest group of non-receptor tyrosine kinases [3,4]. Functionally, Tec kinases play pivotal roles in the development and signaling of hematopoietic cells [3,5], and are characterized by a common domain organization: from the amino-terminus, there are the pleckstrin homology (PH), Tec homology (TH), Src homology 3 (SH3), SH2, and SH1 domains, especially the SH1 domain, which is also the catalytic domain [6,7]. The unique domain and myristoylation site (and frequently palmitoylation site) are generally found in Src family kinases but not in Tec family kinases. Moreover, Tec family kinases lack the C-terminal regulatory tyrosine residue characteristic of Src [8]. TEC, BTK, ITK, and BMX contain PH domains, which inductively recruit these kinases to the plasma membrane by binding the phosphatidylinositol-3-kinase (PI3K) product phosphatidylinositol3,4,5-triphosphate (PIP3), thereby promoting their activation [9]. While RLK contains a distinct N-terminal cysteine string motif that facilitates palmitoylation and consequent association with lipid rafts [10,11]. The TH domain contains several SH3-binding, proline-rich sequences (PXPPXP) shared by this kinase family, with the exception of BMX. The presence of PXXP motif and the SH3 domain establishes an intramolecular interaction which holds the Tec family kinases in a “closed” form and subject the kinases to regulation by stimuli which activate molecules or ligands that disrupt this interaction [12,13] (Figure 1). Bruton's tyrosine kinase (BTK) is by far the most studied member of Tec family and is mainly expressed in B cells [14]. In addition, it is also expressed in myeloid, mast cells [15,16]. BTK is expressed throughout the development of B cell and is not expressed in T cells and other non-hematopoietic cell lineages [17]. In 1993, several research groups discovered the new tyrosine kinase, BTK, which is mutated in a human X-linked agammaglobulinemia (XLA), as known as Bruton's disease. This was the first evidence for the involvement of a protein tyrosine kinase related to the Src-family of oncogenic proteins in a human genetic disease. BTK is also mutated in the mouse X-linked immunodeficiency (Xid). It was subsequently recognized that BTK is a member of the Tec family kinases [18-20]. This review will cover the structure, functions, expression, and mutations of BTK.

Structure and functions of BTK
The BTK gene was mapped to the X-chromosome at Xq21.3-Xq22, consisting of 19 exons, spreading 37.5 kb. 18 of the 19 exons code for a 77 kDa protein, 659 residues long [21]. As a member of the Tec non-receptor tyrosine kinases family, BTK is also comprised of five domains: PH, TH, SH3, SH2, and SH1 [22]. These domains bind different interaction partners (cytosolic proteins or transcription factors) respectively and equip BTK with a critical role in multiple hematopoietic signaling pathways (Figure 2). Hematopoietic signaling pathways including the B cell antigen receptor (BCR), several cytokine receptors, and heterotrimetric G protein associated receptor signaling [23,24]. These signal pathways are transmitted by growth factor receptors, cytokine receptors, G-protein receptors, antigen receptors and integrins [22]. In addition, BTK is regulated by some non-receptor tyrosine kinases, such as JAK, SYK, LYN and FAK family kinases. In turn, BTK regulates many vital signal pathways including those PI3K, PLCγ, and PKC. Those pathways play critical functions in cell proliferation, development, differentiation, survival, and apoptosis [2,5,26].

*Corresponding author: Ying Liu, The Shenzhen Key Lab of Gene and Antibody Therapy, Center for Biotech & BioMedicine and Division of Life Sciences, Graduate School at Shenzhen, Tsinghua University, Shenzhen, 518055, Guangdong, China, Tel: 86-755-26086012, Fax: 86-755-26036012; E-mail: liu.ying2012@sz.tsinghua.edu.cn

Received October 11, 2013; Accepted November 15, 2013; Published November 18, 2013


Copyright: © 2013 Liu Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Its expression throughout B cell development, BTK plays critical functions in B cell proliferation, differentiation, survival, and apoptosis [27]. In BCR singal pathway, following antigen binding of BCR, the cytoplasmic tails of Igα/Igβ Heterodimers are phosphorylated by Src family members [28]. Then the phosphorylation sites act as docking sites for BTK. Following the PH domain binding of PIP3, BTK is targeted to the membrane. The Y551 site is then trans-phosphorylated by Src family tyrosine kinases. The next step is BTK auto-phosphorylation itself on Y223 residue in the SH3 domain. Then BTK begins to transmit signals [23]. Previous reports have indicated that BTK participate in G-protein signal pathway through directly binding different subunits of G-proteins, and then is activated by subunits of heterotrimeric G proteins, such as Gβγ, Gαq, and Gα12 [29,30]. Then the G protein-regulated PI3ky, isof orm of PI3 kinase, can induce phosphorylation of BTK and dramatically enhance the ability of BTK to transmit signals in an ectopic over-expression system [31,32]. However, whether BTK-dependent, G-protein coupled receptor-initiated signals are important during B cell development remains to be determined [33,34]. In addition to its function in pre-BCR signaling, BTK has been implicated as a mediator of signals from various other receptors, including FceR, IL-5R, IL-6R, IL-10R, collagen receptor, erythropoietin receptor, and Toll-like receptor 4 [35-39]. IL-6 was showing to activate BTK in B lymphocytes. Stable complexes were formed by activated IL-6 receptors via JAK family kinases with BTK. Then through this association BTK is phosphorylated by JAK [2,40]. BTK widely participates in multiple downstream signal pathways. And the well-studied downstream signal is perhaps the PLCγ and PKCθ, with a side induction of sustained calcium influx [41] and final MAPK/JNK activation [42]. In PLCγ signal, phosphorylated BTK recruits the adapter B-cell linker protein (BLNK) [also known as SH2 domain-containing leukocyte specific phosphoprotein of 65 kDa (SLP-65)] together with PLCγ2 to the plasma membrane, bringing them in close to Syk, Syk activation results in phosphorylation of BLNK, recruitment and activation of PLCγ2 leading to IP3 production, and release of calcium from the ER calcium store [26,43]. Accident P13K activation leads to production of phosphatidylinositol3,4,5-trisphosphate (PIP3) and diacylglycerol (DAG), causing calcium mobilization and PKCa activation, respectively [23,44]. In addition, BTK can also mediate BCR-stimulated calcium influx [32] and B cell development [45] independently of its catalytic activity. Acting as an adaptor, BTK recruits and activates phosphatidylinositol 4-phosphate 5-kinase (PIPK5) [32], which produces the substrate for PLCγ2. Thus, BTK signals through PLCγ2 directly, by phosphorylation, and indirectly, by increasing substrate availability [46]. The secondary messenger IP3 mediates the opening of intracellular calcium stores, which subsequently activates PKCβ. Then activated PKCβ phosphorylates IκB kinase a and thereby induces NF-κB activation, following by up-regulation of the anti-apoptotic protein Bcl-xl and cyclin D2 [34,47-49] (Figure 3).

**BTK in B cell development**

BTK is expressed throughout B cell development. It sustains the developmental program of pre-B cells by limiting the pre-B cell expansion and by promoting B-cell differentiation. The levels of BTK keep constant at all stages of B cell development in the bone marrow but drop significantly as cells enter the periphery [14,17]. XLA is characterized by a severe block in B cell development at the pre-B cell stage while xid have normal number of pre-B and immature B cells [50,51]. In addition, the xid cells compared to normal cells have a competitive disadvantage at the pre-B to immature transition [52]. Thus, BTK does contribute to the early stages of B cell development. A dual role for BTK in B cell survival and functional responses is also supported by a BTK transgenic mouse model. In xid and BTK−/− mice, splenic B cells transgene expressing wild type BTK protein at 25% of endogenous levels can completely restores conventional B cell development [53]. Responses to TNP-Ficoll in vivo and BCR crosslinking in vitro are above those of xid mice but remain significantly impaired relative to wild type controls. Wild-type BTK protein levels two fold increase in obtained by generating mice homozygous for the transgene results in four fold greater response to both TNP-Ficoll and anti-IgM as well as increased sensitivity to BCR cross linking. The above observations indicate that the dosage of BTK is limiting for BCR signaling and that there is a higher threshold level of BTK required for B cell functional than for responses survival [53,54]. Thus, the sensitivity of B cell function to BTK levels suggests that BTK may be an attractive therapeutic target for diseases involving hyperactive B cells, such as autoimmunity.

**Expression of BTK**

The Tec family kinases, are widely expressed in a wide range of vertebrate tissues [2]. In mammals, Tec kinases are expressed prominently in hematopoietic cells where they are expressed with a relatively high degree of lineage specificity [55,56]. TEC and BMX are expressed ubiquitously. B cells express primarily BTK while T cells express both ITK and RLK [57]. In addition, besides expression in hematopoietic tissues, Tec kinase family members were also reported to be expressed in liver, kidney, heart, lung and ovarian tissues [58, 59]. BTK is expressed at all stages of B lineage development from CD34+ pro-B to mature B cells while xid have normal number of pre-B and immature B cells [50,51]. In addition, the xid cells compared to normal cells have a competitive disadvantage at the pre-B to immature transition [52]. Thus, xid have normal number of pre-B and immature B cells [50,51]. In addition, the xid cells compared to normal cells have a competitive disadvantage at the pre-B to immature transition [52]. Thus, the sensitivity of B cell function to BTK levels suggests that BTK may be an attractive therapeutic target for diseases involving hyperactive B cells, such as autoimmunity.
line and 2 out of 9 (22.2%) MM patients’ cells. Interestingly, patients
Recent findings from our institute demonstrate that BTK is elevated
mast cells, BTK also expressed in macrophages, and neutrophils [34].
pre-B cell leukemia. Except for expressing in B lineage, myeloid, and
target to be considered for therapeutic intervention in BCR-ABL1+
of the leukemia cells [64,65]. Thus, BTK activity represents an obvious
16) isoforms. Kinase-deficient splice variants are co-expressed with full-
splicing of BTK, resulting in the presence of BTK-p52 (lack of exon 15,
pre-B cell leukemia cells. In these diseases, BCR-ABL1 induces aberrant
truncated kinase-inactive BTK was identified in human BCR–ABL1+
enter the periphery. Recent studies indicate that a novel function of
B cell development in the bone marrow but drop significantly as cells
enter the periphery. Recent studies indicate that a novel function of
truncated kinase-inactive BTK was identified in human BCR–ABL1+
pre-B cell leukemia cells. In these diseases, BCR-ABL1 induces aberrant
splicing of BTK, resulting in the presence of BTK-p52 (lack of exon 15,
loss of reading frame) and BTK-p62 (in frame deletions of exons 15 and
16) isoforms. Kinase-deficient splice variants are co-expressed with full-
length BTK, acting as a dominant-negative BTK in that they suppress
BTK-dependent differentiation and pre-B cell receptor responsiveness
of the leukemia cells [64,65]. Thus, BTK activity represents an obvious
target to be considered for therapeutic intervention in BCR-ABL1+
pre-B cell leukemia. Except for expressing in B lineage, myeloid, and
mast cells, BTK also expressed in macrophages, and neutrophils [34].
Recent findings from our institute demonstrate that BTK is elevated
and activated in dexamethasone-resistant multiple myeloma (MM) cell
line and 2 out of 9 (22.2%) MM patients’ cells. Interestingly, patients
with higher BTK expression have poorer prognosis [56].

Mutations in BTK
To date, the only Tec kinase known to cause human disease is BTK. X-linked agammaglobulinemia (XLA) is the proto typic
humoral immunodeficiency described in 1952 by Bruton [66,67]. This
hereditary immunodeficiency disease is caused by arrest in early B-cell
differentiation and is characterized by recurrent bacterial infections
and profound hypogammaglobulinemia with marked reduction or
lack of mature B-cells in the peripheral blood [19,20]. Thus, patients
with XLA are clinically characterized by a pronounced reduction in
 serum immunoglobulins therefore suffer from recurrent bacterial and
enteroviral infections [68]. In mice, functional B lymphocytes, also
reduced in numbers. But xid mice exhibit a less severe phenotype than
that of patients with XLA [69,70]. In 1993, several research groups
reported mutations in the gene encoding BTK associating to XLA
in human and xid in mice. A range of biochemical and functional
studies indicate that BTK deficiency interferes with B lineage-specific
signal transduction pathways critical for both early B lineage growth
and clonal expansion and mature B lineage survival and activation.
And previous studies indicated that 90-95% of males with presumed
XLA have mutations in BTK [71]. To date more than 1252 different
mutations have been identified. These mutations are listed in BTKbase,
a XLA mutation registry, which was established in 1994 (http://bioinf.
uta.fi/BTKbase/; last update 24 Oct., 2012). The mutations overlay all
the domains of BTK, as well as in non-coding sequences. Mutation
types consist of Missense mutations (40%), small insertions and
deletions (27%), Splice-site mutations (16%), nonsense mutations
(17%) [72]. However, as far as is known, no overt genotype-phenotype
 correlation, probably due to the fact that almost all patients analyzed
belong to the group with classical (severe) disease. In the mouse, BTK
gene inactivated causes a mild phenotype resembling the spontaneous
xid mutant carrying the missense mutation R28C in the PH domain.
These mice lack B-1 cells, reducing to 30-50% of the normal numbers,
have reduced numbers of spleen B cells and show decreased levels
of IgM and IgG3 [18,73,74]. Thus, the phenotype of mutated mice is
still considerably milder than that of affected humans, who essentially
lack B lymphocytes and immunoglobulins, irrespective of the type
of mutation. Our institute screened for sequence variations of coding
sequence of BTK gene by cDNA sequencing in MM cell lines and 8
unrelated patients. The sequencing results showed that 6 out 8 patients
(75%) carried a SNP at position 2062 (T2062C) in BTK gene coding
domain [56]. Although this SNP does not alter the coding amino acid of
the codon, it appears to be common in MM, and possibly MM-specific.
Therefore, the function of BTK in MM warrants further investigation.

Therapeutic Potential of Inhibiting BTK
Functional abnormalities of PTKs have been described by previous
reports in cancer, immunodeficiency, diabetes, arteriosclerosis and
psoriasis [74]. And the therapeutic potential targeting BTK or
upstream/downstream effectors associated with BTK were proposed and
has achieved remarkable efficacy with an acceptable safety
profile in B cell malignancies by lots of scientists [14,49,74]. The anti-
apoptosis function of BTK is supported by the observation that bcl-2
and bcl-xl transgenes can restore normal B cell levels in xid mice [54].
Furthermore, BTK can induce Bcl-xl expression and inhibits the pro-
apoptotic effects of Fas ligation in mature B cells [51]. Due to the vital
role of BTK in hematopoiesis of B cells, several reports suggested that
alteration of its function would cause various diseases associated with
abnormal development of B cells [34,49]. So in the past ten years, a
number of researches have addressed the possible functions of BTK
in blood cancer development [14,15,49,56,74]. Bibrutinib, an orally
available inhibitor which irreversibly and selectively binds to BTK,
has achieved high response rates in phase I/II clinical trials in relapsed
non Hodgkin’s lymphoma, and phase III clinical trials in mantle cell
lymphoma and chronic lymphocytic leukaemia [73,74]. In addition,
Tai et al. [14] found that Bibrutinib not only targets MM tumor cells
but also bone marrow microenvironment that support MM cell growth
and survival, as well as MM-deteriorated bone lysis. These results
demonstrate BTK inhibitors are extremely attractive approach not only for B-cell malignancies, but also for myeloma and related bone disease.

**Conclusion**

In conclusion, this review has briefly summarized work defining the structure of BTK, the range of signaling pathways potentially utilizing BTK, and the mutations leading to altered BTK function. In addition, we have discussed several aspects on the biology of BTK, and the specific expression pattern of BTK. As a highly conserved non-receptor tyrosine kinase, through interacting with diverse interaction partners, BTK plays diverse roles in different species. Although in the last decade quite a lot has been learned about the events related to BCR signaling, the precise role of BTK in this pathway remains poorly understood. Although large numbers of mutations have been assembled in the BTKbase in the last decade, there is no evidence for a correlation between the type and position of a mutation and phenotypic parameters. Although the specific expressional pattern of BTK. As a highly conserved non-receptor tyrosine kinase, through interacting with diverse interaction partners, BTK plays diverse roles in different species. Although in the last decade quite a lot has been learned about the events related to BCR signaling, the precise role of BTK in this pathway remains poorly understood. Although large numbers of mutations have been assembled in the BTKbase in the last decade, there is no evidence for a correlation between the type and position of a mutation and phenotypic parameters.

**References**


